ATE409688T1 - Substituierte alpha-hydroxy-säuren als caspase- hemmer und ihre verwendung - Google Patents

Substituierte alpha-hydroxy-säuren als caspase- hemmer und ihre verwendung

Info

Publication number
ATE409688T1
ATE409688T1 AT00959495T AT00959495T ATE409688T1 AT E409688 T1 ATE409688 T1 AT E409688T1 AT 00959495 T AT00959495 T AT 00959495T AT 00959495 T AT00959495 T AT 00959495T AT E409688 T1 ATE409688 T1 AT E409688T1
Authority
AT
Austria
Prior art keywords
substituted alpha
hydroxy acids
caspase inhibitors
inhibitors
cell death
Prior art date
Application number
AT00959495T
Other languages
English (en)
Inventor
Yan Wang
Sui Cai
Eckard Weber
Gordon Mills
Douglas Green
Lufeng Guan
Original Assignee
Cytovia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytovia Inc filed Critical Cytovia Inc
Application granted granted Critical
Publication of ATE409688T1 publication Critical patent/ATE409688T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00959495T 1999-08-27 2000-08-28 Substituierte alpha-hydroxy-säuren als caspase- hemmer und ihre verwendung ATE409688T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15107799P 1999-08-27 1999-08-27
US15837399P 1999-10-12 1999-10-12

Publications (1)

Publication Number Publication Date
ATE409688T1 true ATE409688T1 (de) 2008-10-15

Family

ID=26848309

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00959495T ATE409688T1 (de) 1999-08-27 2000-08-28 Substituierte alpha-hydroxy-säuren als caspase- hemmer und ihre verwendung

Country Status (15)

Country Link
US (1) US6495522B1 (de)
EP (1) EP1212295B1 (de)
JP (1) JP2003508379A (de)
KR (1) KR20020033777A (de)
CN (1) CN1235875C (de)
AT (1) ATE409688T1 (de)
AU (1) AU775291B2 (de)
BR (1) BR0013666A (de)
CA (1) CA2383002A1 (de)
DE (1) DE60040397D1 (de)
EA (1) EA200200301A1 (de)
IL (1) IL148426A0 (de)
MX (1) MXPA02002038A (de)
NO (1) NO20020938L (de)
WO (1) WO2001016093A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184210B1 (en) * 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
EP1100520B1 (de) * 1998-07-21 2004-09-22 Cytovia, Inc. Neue fluoreszensfarbstoffe und ihre anwendung in fluoreszensnachweisverfahren ganzer zellen für kaspasen, peptidasen, proteasen und andere enzyme sowie deren verwendung
EP1165490B1 (de) * 1999-03-16 2006-08-16 Cytovia, Inc. Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung
CA2369619A1 (en) 1999-04-09 2000-10-19 Cytovia, Inc. Caspase inhibitors and the use thereof
US6689784B2 (en) * 2000-03-29 2004-02-10 Vertex Pharmaceuticals Incorporated Carbamate caspase inhibitors and uses thereof
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
US20040198650A1 (en) * 2001-03-29 2004-10-07 Poul Jensen Means for inhibiting proteolytical processing of parkin
US6777443B2 (en) * 2001-05-15 2004-08-17 Novartis Ag Dipeptide derivatives
CA2447999C (en) * 2001-05-23 2011-04-26 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
WO2003008373A1 (de) * 2001-07-19 2003-01-30 Merck Patent Gmbh Tyrosinhydrazide
EP1485107A1 (de) 2002-02-11 2004-12-15 Vertex Pharmaceuticals Incorporated Phospholipide als caspase-hemmer-prodrugs
EP1494700A2 (de) * 2002-04-05 2005-01-12 Cytovia, Inc. Caspase-hemmer zur behandlung von erkrankungen und zuständen, die durch kontakt mit radionucliden, biologischen mitteln oder chemischen mitteln verursacht wurden
EP1499898A2 (de) * 2002-04-19 2005-01-26 Vertex Pharmaceuticals Incorporated Regulierung von tnf-alpha
US7504382B2 (en) * 2003-05-06 2009-03-17 Cytovia, Inc. Protease inhibitors for coronaviruses and SARS-CoV and the use thereof
EP1723124A1 (de) * 2004-02-18 2006-11-22 Georgia Tech Research Corporation Propenoylhydrazide
AU2005223767B2 (en) * 2004-03-12 2011-12-01 Vertex Pharmaceuticals Incorporated Processes and intermediates for the preparation of aspartic acetal caspase inhibitors
PL217743B1 (pl) 2004-05-15 2014-08-29 Vertex Pharma Zastosowanie inhibitorów ICE/kaspazy-1 do leczenia napadów i konwulsji w epilepsji oraz zawierające je kompozycja farmaceutyczna i zestaw
CN1980658A (zh) 2004-05-27 2007-06-13 沃泰克斯药物股份有限公司 治疗自身炎性疾病的ice抑制剂
US8741967B2 (en) 2007-12-12 2014-06-03 Children's Hospital & Research Center At Oakland Use of unsaturated sphingosine compounds as chemotherapeutic agents for the treatment of cancer
AU2009291632B2 (en) * 2008-09-11 2013-04-04 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
HUP1000243A2 (en) 2010-05-06 2012-01-30 Avidin Kft 8-hidroxy-quinoline derivatives
JP6006908B2 (ja) 2010-11-05 2016-10-12 ブランダイス ユニバーシティＢｒａｎｄｅｉｓ Ｕｎｉｖｅｒｓｉｔｙ Ｉｃｅ阻害化合物およびその使用
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
BR112016011417A8 (pt) 2013-11-21 2020-05-05 Allergan Inc derivados de fenilcarbamatos como moduladores do receptor de formil peptídeo, composição farmacêutica, e seus usos
CN104803864B (zh) * 2014-01-29 2017-01-11 华东师范大学 β-羟基-α-氨基酸衍生物及其合成方法和应用
GB201712282D0 (en) 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2381023A1 (fr) 1977-02-18 1978-09-15 Delalande Sa Nouveaux oligopeptides trifluoromethyles derives de la l-alanine, leur procede de preparation et leur application en therapeutique
US4518528A (en) 1983-05-19 1985-05-21 Rasnick David W α Amino fluoro ketones
US5221607A (en) 1989-09-18 1993-06-22 Scios Nova Inc. Assays and reagents for amyloid deposition
US5416013A (en) 1990-04-04 1995-05-16 Sterling Winthrop Inc. Interleukin 1β protease and interleukin 1β protease inhibitors
US5252463A (en) 1990-06-22 1993-10-12 The Du Pont Merck Pharmaceutical Company Clipsin, a chymotrypsin-like protease and method of using same
US5824297A (en) 1990-06-25 1998-10-20 Oncogene Science, Inc. Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
DE69226820T2 (de) 1991-06-21 1999-05-12 Merck & Co., Inc., Rahway, N.J. Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen
RU2206611C2 (ru) 1991-08-30 2003-06-20 Вертекс Фармасьютикалз Инкорпорейтед ФРАГМЕНТ ДНК, ПЛАЗМИДНЫЙ ВЕКТОР, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ПОЛИПЕПТИД, ОБЛАДАЮЩИЙ IL-1β ПРОТЕАЗНОЙ АКТИВНОСТЬЮ
CA2129976C (en) 1992-02-21 2002-09-17 Kevin T. Chapman Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme
EP0618223A3 (de) * 1993-03-08 1996-06-12 Sandoz Ltd Peptide, die Freisetzung vom Interleukin 1-Bêta, nützlich als entzündungshemmende Wirkstoffe.
CA2122227A1 (en) * 1993-04-29 1994-10-30 Roland E. Dolle Peptide analogs as irreversible interleukin-1.beta. protease inhibitors
US5462939A (en) 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
JPH0789951A (ja) * 1993-06-03 1995-04-04 Sterling Winthrop Inc インターロイキン−１β転換酵素阻害剤
US6087160A (en) 1993-06-24 2000-07-11 The General Hospital Corporation Programmed cell death genes and proteins
WO1995005192A1 (en) 1993-08-13 1995-02-23 Merck & Co., Inc. SUBSTITUTED KETONE DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME
US5759548A (en) 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
US5565430A (en) * 1994-08-02 1996-10-15 Sterling Winthrop Inc. Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US5843904A (en) 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
US6200969B1 (en) 1996-09-12 2001-03-13 Idun Pharmaceuticals, Inc. Inhibition of apoptosis using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors
US5869519A (en) 1996-12-16 1999-02-09 Idun Pharmaceuticals, Inc. C-terminal modified (n-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
ATE310528T1 (de) 1996-09-12 2005-12-15 Idun Pharmaceuticals Inc Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie
JP2000501428A (ja) 1996-09-12 2000-02-08 アイドゥン ファーマシューティカルズ，インコーポレイテッド 酵素のｉｃｅ／ｃｅｄ−３プロテアーゼファミリーを阻害する新規な三環式化合物
US5877197A (en) 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6184244B1 (en) 1996-12-16 2001-02-06 Idun Pharmaceuticals, Inc. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
SK122199A3 (en) 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
JPH111491A (ja) 1997-04-18 1999-01-06 Takeda Chem Ind Ltd ペプチド類及びその剤
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
AU741203B2 (en) 1997-10-10 2001-11-22 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
JPH11180891A (ja) 1997-12-25 1999-07-06 Dai Ichi Seiyaku Co Ltd 抗細胞死剤
KR20010041905A (ko) 1998-03-16 2001-05-25 시토비아 인크. 디펩티드 카스파제 억제제 및 이의 용도
BR9911010A (pt) 1998-05-05 2005-12-06 Warner Lambert Co Inibidores de sucinamida de enzima de conversão da interleucina-1beta
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6201118B1 (en) 1998-08-19 2001-03-13 Vertex Pharmaceuticals Inc. Process for forming an N-acylated, N,N-containing bicyclic ring from piperazic acid or an ester thereof especially useful as an intermediate in the manufacture of a caspase inhibitor
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
WO2000032620A1 (en) 1998-12-02 2000-06-08 Merck Frosst Canada & Co. Gamma-ketoacid tetrapeptides as inhibitors of caspase-3
EP1163214A1 (de) 1999-03-16 2001-12-19 Merck Frosst Canada & Co. Gamma-ketosäure-dipeptide als inhibitoren von caspase-3
EP1165490B1 (de) 1999-03-16 2006-08-16 Cytovia, Inc. Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung
CA2369619A1 (en) 1999-04-09 2000-10-19 Cytovia, Inc. Caspase inhibitors and the use thereof
PT1163208E (pt) 1999-08-06 2004-08-31 Vertex Pharma Inibidores de caspase e as suas utilizacoes
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
AR026748A1 (es) 1999-12-08 2003-02-26 Vertex Pharma Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis
US6689784B2 (en) 2000-03-29 2004-02-10 Vertex Pharmaceuticals Incorporated Carbamate caspase inhibitors and uses thereof
NZ516918A (en) 2000-05-23 2004-06-25 Vertex Pharma Caspase inhibitors and uses thereof
DE60131160T2 (de) 2000-06-07 2008-08-07 Vertex Pharmaceuticals Inc., Cambridge Caspase-inhibitoren und ihre verwendungen

Also Published As

Publication number Publication date
US6495522B1 (en) 2002-12-17
CA2383002A1 (en) 2001-03-08
WO2001016093A1 (en) 2001-03-08
DE60040397D1 (de) 2008-11-13
BR0013666A (pt) 2002-05-14
KR20020033777A (ko) 2002-05-07
AU7080900A (en) 2001-03-26
IL148426A0 (en) 2002-09-12
MXPA02002038A (es) 2002-10-31
CN1382119A (zh) 2002-11-27
AU775291B2 (en) 2004-07-29
NO20020938L (no) 2002-04-15
NO20020938D0 (no) 2002-02-26
EA200200301A1 (ru) 2002-08-29
CN1235875C (zh) 2006-01-11
EP1212295A1 (de) 2002-06-12
EP1212295B1 (de) 2008-10-01
JP2003508379A (ja) 2003-03-04

Similar Documents

Publication Publication Date Title
DE60040397D1 (de) Substituierte alpha-hydroxy-säuren als caspase-hemmer und ihre verwendung
ATE363465T1 (de) Caspase inhibitoren und ihre verwendung
DE60030097D1 (de) Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung
ATE295177T1 (de) Dipeptid kaspase inhibitoren und deren verwendung
ATE253545T1 (de) Biarylessigsäure-derivate und ihre verwendung als cox-2 inhibitoren
WO2002100826A3 (en) Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
ATE309237T1 (de) Aromatische heterozyklische verbindungen als antientzündungwirkstoffe
DE60036726D1 (de) Harnstoff derivate als entzündungshemmende mittel
BR0207278A (pt) Derivados de ftalazinona-piperidina como inibidores de pde4
NO20072605L (no) Nytt antranilinsyrederivat eller et salt derav
ATE260269T1 (de) Substituierte 4h-chromene und ähnliche verbindungen als kaspasis aktivatoren und apoptosis induktoren und deren verwendung
ATE450531T1 (de) Substituierte 4h-chromene und analoga als aktivatoren von caspasen und induktoren von apoptose, und deren verwendung als antikrebsmittel
DE60327811D1 (de) Sulfhydantoine als phosphatisostere zur verwendung als phosphatasehemmer bei der behandlung von krebs und autoimmunerkrankungen
ATA16597A (de) Neue substituierte p-sulfonylaminobenzol- sulfonsäureamide
WO2001079187A8 (en) Substituted 1,4-thiazepine and analogs and their use as activators of caspases
ATE368643T1 (de) Faktor xa benzamidin inhibitoren
ATE181056T1 (de) Arylessigsäurederivate und ihre verwendung als fungizide
BR0014990A (pt) Derivados de tetrahidrotiopirano ranftalazinona como inibidores de pde4
EA200000204A1 (ru) Производные пирролопирролона в качестве ингибиторов эластазы нейтрофилов
CA2399451A1 (en) Tyrosine derivatives with anti-leukotriene activity
WO1999065451A3 (en) Caspases and apoptosis
DE60036558D1 (de) Phthalazinon-derivate als pde 4 hemmer
BR0010488A (pt) Tienocicloalqu(en)ilamino-1,3,5-triazinas substituìdas
DE59901563D1 (de) N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung
BR0110328A (pt) Compostos heterocìclicos com atividade antiinflamatória

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties